Hospital
ST Vincent Hospital
ST Vincent Hospital was paid $46.58M by Medicaid between Jan 2018 and Dec 2024, across 446 billing codes. Its largest line is 99284, emergency room visit (serious) — 12% of everything it billed.
33Billing provider infoST VINCENT HOSPITAL
SANTA FE, NM 87505
SANTA FE, NM 87505
33aNPI1578587150assigned 07/27/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$46.58M
24GClaims1,126,444
24DCodes billed446
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in New Mexico
Rank by total paid#5 of 24
Median peer was paid$20.13M
This provider vs. median2.3×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 217,902 | $9.03M | |
| 2019 | 109,494 | $4.75M | |
| 2020 | 94,557 | $3.58M | |
| 2021 | 123,713 | $4.50M | |
| 2022 | 168,800 | $7.04M | |
| 2023 | 217,934 | $9.34M | |
| 2024incomplete | 194,044 | $8.35M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 12% | 27,968 | 25,185 | $5.54M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 10% | 33,840 | 31,537 | $4.79M |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 10.0% | 69,974 | 52,833 | $4.65M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 5.7% | 10,648 | 9,723 | $2.66M |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 2.9% | 9,689 | 9,213 | $1.33M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 2.4% | 25,484 | 7,944 | $1.13M |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 2.3% | 4,465 | 2,592 | $1.05M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.2% | 4,249 | 3,983 | $1.01M |
| G0378 | Hospital observation service, per hour | 2.1% | 5,040 | 2,714 | $981K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 2.1% | 19,579 | 17,348 | $981K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.9% | 13,105 | 10,174 | $904K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.9% | 3,283 | 3,025 | $903K |
434 more codes
| 80053 | Comprehensive metabolic panel | 1.8% | 76,132 | $832K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.7% | 8,560 | $813K |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 1.7% | 1,265 | $788K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.5% | 7,512 | $691K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.4% | 4,695 | $672K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.4% | 8,529 | $648K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.3% | 14,500 | $596K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.2% | 77,041 | $556K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | 1.1% | 16,610 | $498K |
| 71045 | Radiologic examination, chest; single view | <1% | 8,825 | $386K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 5,284 | $380K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 5,910 | $318K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 20,617 | $297K |
| 36415 | Collection of venous blood by venipuncture | <1% | 72,282 | $293K |
| 84484 | <1% | 13,980 | $276K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 7,338 | $268K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 8,373 | $266K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 8,389 | $264K |
| 97602 | <1% | 5,485 | $254K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 527 | $240K |
| 87481 | <1% | 2,890 | $218K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 9,112 | $209K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,092 | $204K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 6,093 | $203K |
| 59025 | Fetal non-stress test | <1% | 1,976 | $188K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 7,117 | $179K |
| D2930 | Prefabricated stainless steel crown - primary tooth | <1% | 1,185 | $179K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 439 | $178K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 1,289 | $171K |
| 64493 | <1% | 521 | $160K | |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 242 | $157K |
| 90791 | Psychiatric diagnostic evaluation | <1% | 1,737 | $151K |
| 93017 | <1% | 1,111 | $149K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 2,302 | $141K |
| 80061 | Lipid panel | <1% | 13,510 | $138K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,192 | $136K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 574 | $130K |
| 64483 | <1% | 436 | $128K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 2,042 | $127K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 3,422 | $126K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 2,738 | $125K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 509 | $124K |
| 20610 | <1% | 858 | $118K | |
| 82550 | <1% | 11,698 | $118K | |
| 73610 | <1% | 1,192 | $112K | |
| 84703 | <1% | 7,938 | $109K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 5,980 | $109K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 11,969 | $108K |
| 83690 | <1% | 13,716 | $107K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 12,556 | $106K |
| 87800 | <1% | 1,965 | $104K | |
| 83605 | <1% | 5,304 | $102K | |
| 82553 | <1% | 5,466 | $102K | |
| 73030 | <1% | 1,305 | $102K | |
| 82803 | <1% | 4,081 | $102K | |
| 73110 | <1% | 1,499 | $96K | |
| 96415 | <1% | 772 | $89K | |
| 83880 | <1% | 3,383 | $86K | |
| 96417 | <1% | 595 | $86K | |
| 73130 | <1% | 1,320 | $84K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 1,793 | $84K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 1,486 | $82K |
| 96367 | <1% | 1,212 | $81K | |
| 20550 | <1% | 320 | $81K | |
| J2505 | Injection, pegfilgrastim, 6 mg | <1% | 43 | $80K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 553 | $79K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 6,653 | $79K |
| 81003 | <1% | 18,237 | $79K | |
| 92557 | <1% | 867 | $78K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 2,293 | $78K |
| 47562 | <1% | 27 | $73K | |
| 84439 | <1% | 9,014 | $72K | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 4,073 | $71K |
| C1776 | Joint device (implantable) | <1% | 62 | $70K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 746 | $66K |
| 87400 | <1% | 3,739 | $66K | |
| 82607 | <1% | 4,187 | $65K | |
| 82728 | <1% | 5,353 | $64K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 1,496 | $63K |
| 97162 | <1% | 1,652 | $62K | |
| 99152 | <1% | 1,622 | $61K | |
| 95811 | <1% | 119 | $60K | |
| 64494 | <1% | 482 | $58K | |
| 73564 | <1% | 811 | $58K | |
| 73562 | <1% | 669 | $57K | |
| 77336 | <1% | 645 | $57K | |
| 73140 | <1% | 822 | $56K | |
| 92567 | <1% | 1,375 | $55K | |
| 86803 | <1% | 3,429 | $55K | |
| 80074 | <1% | 1,300 | $52K | |
| 81025 | <1% | 4,834 | $52K | |
| 70486 | <1% | 268 | $52K | |
| 85610 | <1% | 13,753 | $51K | |
| 86703 | <1% | 2,502 | $50K | |
| 86140 | <1% | 4,712 | $50K | |
| 84702 | <1% | 2,748 | $49K | |
| 88307 | <1% | 230 | $49K | |
| 82077 | <1% | 1,702 | $48K | |
| 36591 | <1% | 916 | $48K | |
| 86780 | <1% | 3,564 | $48K | |
| 87040 | <1% | 1,800 | $48K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 2,511 | $45K |
| 85379 | <1% | 2,268 | $44K | |
| 85027 | <1% | 7,630 | $44K | |
| 83721 | <1% | 5,992 | $43K | |
| 94060 | <1% | 481 | $43K | |
| 93971 | <1% | 560 | $43K | |
| 73630 | <1% | 755 | $42K | |
| 73560 | <1% | 835 | $42K | |
| 31575 | <1% | 467 | $41K | |
| 82948 | <1% | 10,006 | $41K | |
| 83735 | <1% | 6,404 | $40K | |
| 84145 | <1% | 1,806 | $40K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 5,246 | $39K |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 1,437 | $39K |
| 80050 | General health panel | <1% | 1,106 | $38K |
| 87070 | <1% | 2,841 | $37K | |
| 87186 | <1% | 4,076 | $37K | |
| 94726 | <1% | 485 | $37K | |
| 97161 | <1% | 1,174 | $37K | |
| 82375 | <1% | 3,197 | $36K | |
| 82330 | <1% | 2,580 | $36K | |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 3,083 | $36K |
| 96416 | <1% | 122 | $35K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 1,171 | $33K |
| 86769 | <1% | 1,337 | $33K | |
| 52000 | <1% | 119 | $32K | |
| 96376 | <1% | 1,369 | $32K | |
| 76830 | Ultrasound, transvaginal | <1% | 338 | $32K |
| 73502 | <1% | 764 | $31K | |
| C1769 | Guide wire | <1% | 882 | $31K |
| J0585 | Injection, onabotulinumtoxina, 1 unit | <1% | 78 | $30K |
| 84403 | <1% | 1,439 | $30K | |
| 72100 | <1% | 433 | $30K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 323 | $30K |
| 82310 | <1% | 3,374 | $30K | |
| 94729 | <1% | 662 | $29K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 559 | $28K |
| D3220 | Therapeutic pulpotomy (excluding final restoration) - removal of pulp coronal to the dentinocemental junction | <1% | 282 | $28K |
| 77300 | <1% | 111 | $27K | |
| 81001 | <1% | 5,517 | $27K | |
| 83970 | <1% | 789 | $27K | |
| 77334 | <1% | 95 | $27K | |
| 83550 | <1% | 4,198 | $27K | |
| 86850 | <1% | 3,495 | $27K | |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | <1% | 1,622 | $26K |
| 88304 | <1% | 768 | $25K | |
| 84480 | <1% | 2,286 | $25K | |
| 74018 | <1% | 457 | $25K | |
| 82731 | <1% | 298 | $24K | |
| 64635 | <1% | 44 | $24K | |
| 73080 | <1% | 340 | $23K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 859 | $23K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 65 | $22K |
| 83050 | <1% | 3,193 | $22K | |
| 97165 | <1% | 615 | $22K | |
| 73590 | <1% | 339 | $22K | |
| 82947 | <1% | 4,283 | $22K | |
| 80051 | <1% | 1,050 | $21K | |
| 84132 | <1% | 3,255 | $21K | |
| 99195 | <1% | 363 | $21K | |
| 83540 | <1% | 4,274 | $20K | |
| 84100 | <1% | 2,797 | $20K | |
| 84481 | <1% | 1,270 | $20K | |
| J0897 | Injection, denosumab, 1 mg | <1% | 42 | $19K |
| 85018 | <1% | 5,470 | $19K | |
| 96402 | <1% | 185 | $18K | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 1,659 | $18K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 825 | $18K |
| 20600 | <1% | 111 | $18K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 946 | $18K |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 228 | $17K |
| 62323 | <1% | 56 | $17K | |
| 84295 | <1% | 3,147 | $17K | |
| 86762 | <1% | 815 | $17K | |
| 87077 | <1% | 2,421 | $17K | |
| 82570 | <1% | 3,543 | $17K | |
| 84153 | <1% | 1,439 | $17K | |
| 90715 | <1% | 569 | $17K | |
| 86039 | <1% | 1,459 | $16K | |
| 43235 | <1% | 38 | $16K | |
| 10060 | <1% | 171 | $16K | |
| G0399 | Home sleep test (hst) with type iii portable monitor, unattended; minimum of 4 channels: 2 respiratory movement/airflow, 1 ecg/heart rate and 1 oxygen saturation | <1% | 94 | $16K |
| 87340 | <1% | 1,809 | $16K | |
| 94750 | <1% | 232 | $16K | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 354 | $16K |
| 97010 | <1% | 1,573 | $15K | |
| 85652 | <1% | 4,223 | $15K | |
| 96411 | <1% | 110 | $15K | |
| G0260 | Injection procedure for sacroiliac joint; provision of anesthetic, steroid and/or other therapeutic agent, with or without arthrography | <1% | 57 | $15K |
| 82670 | <1% | 564 | $14K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 45 | $14K |
| 86141 | <1% | 989 | $14K | |
| 76937 | <1% | 940 | $14K | |
| 84156 | <1% | 1,894 | $14K | |
| 94664 | <1% | 165 | $14K | |
| 93798 | <1% | 490 | $14K | |
| 97035 | <1% | 1,047 | $14K | |
| 86235 | <1% | 180 | $14K | |
| 86900 | <1% | 3,705 | $13K | |
| 86901 | <1% | 3,962 | $13K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 7,832 | $13K |
| 82435 | <1% | 3,091 | $13K | |
| 84550 | <1% | 1,499 | $13K | |
| 83001 | <1% | 762 | $13K | |
| 69210 | <1% | 332 | $13K | |
| 97150 | Therapeutic procedure(s), group (2 or more individuals) | <1% | 731 | $12K |
| 87147 | <1% | 1,166 | $12K | |
| 87205 | <1% | 2,258 | $12K | |
| 87653 | <1% | 306 | $12K | |
| 64636 | <1% | 29 | $11K | |
| 85730 | <1% | 1,978 | $11K | |
| 51705 | <1% | 210 | $11K | |
| 97164 | <1% | 471 | $11K | |
| D1120 | Dental cleaning, child | <1% | 69 | $11K |
| 88342 | <1% | 264 | $11K | |
| 29075 | <1% | 58 | $11K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 13,801 | $11K |
| 82378 | <1% | 686 | $10K | |
| 82248 | <1% | 1,429 | $10K | |
| 82962 | <1% | 2,455 | $10K | |
| 80143 | <1% | 311 | $10K | |
| 86431 | <1% | 854 | $9K | |
| 82043 | <1% | 1,566 | $9K | |
| 83615 | <1% | 1,743 | $9K | |
| 12001 | <1% | 104 | $9K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 44 | $9K |
| J0185 | Injection, aprepitant, 1 mg | <1% | 159 | $9K |
| D7140 | Extraction, erupted tooth or exposed root | <1% | 73 | $9K |
| J1453 | Injection, fosaprepitant, 1 mg | <1% | 166 | $9K |
| C8929 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography | <1% | 25 | $9K |
| 51702 | <1% | 156 | $9K | |
| 20553 | <1% | 47 | $9K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 27 | $8K |
| 80179 | <1% | 272 | $8K | |
| 82247 | <1% | 1,238 | $8K | |
| 85014 | <1% | 1,628 | $8K | |
| 86480 | <1% | 164 | $8K | |
| 36410 | <1% | 514 | $8K | |
| 83516 | <1% | 520 | $8K | |
| 87081 | <1% | 1,076 | $8K | |
| 12011 | <1% | 84 | $8K | |
| 85651 | <1% | 1,633 | $8K | |
| 73090 | <1% | 112 | $7K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 412 | $7K |
| 72170 | <1% | 100 | $7K | |
| 82140 | <1% | 415 | $7K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 411 | $7K |
| 84402 | <1% | 288 | $7K | |
| 73070 | <1% | 98 | $7K | |
| 83090 | <1% | 394 | $7K | |
| 97166 | <1% | 164 | $6K | |
| 87522 | Neg quan hep c or qual rna | <1% | 132 | $6K |
| 82024 | <1% | 186 | $6K | |
| 84112 | <1% | 98 | $6K | |
| 86376 | <1% | 285 | $6K | |
| 31231 | <1% | 41 | $6K | |
| 95819 | <1% | 40 | $6K | |
| 43244 | <1% | 14 | $6K | |
| 97163 | <1% | 104 | $6K | |
| 82784 | <1% | 771 | $6K | |
| 86787 | <1% | 367 | $5K | |
| 96368 | <1% | 218 | $5K | |
| 49083 | <1% | 19 | $5K | |
| 93351 | <1% | 12 | $5K | |
| 87449 | <1% | 340 | $5K | |
| 86328 | <1% | 197 | $5K | |
| 71101 | <1% | 80 | $5K | |
| 82533 | <1% | 288 | $5K | |
| 82105 | <1% | 229 | $5K | |
| 70498 | <1% | 19 | $5K | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 1,993 | $5K |
| H0050 | Alcohol and/or drug services, brief intervention, per 15 minutes | <1% | 66 | $4K |
| 64490 | <1% | 18 | $4K | |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 1,417 | $4K |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 324 | $4K |
| 29580 | <1% | 83 | $4K | |
| 64615 | <1% | 13 | $4K | |
| 87807 | <1% | 134 | $4K | |
| J2704 | Injection, propofol, 10 mg | <1% | 755 | $4K |
| 0077U | <1% | 46 | $4K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 48 | $4K |
| 82747 | <1% | 284 | $4K | |
| 94760 | <1% | 675 | $4K | |
| 29125 | <1% | 28 | $3K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 525 | $3K |
| 84144 | <1% | 122 | $3K | |
| 80069 | <1% | 461 | $3K | |
| 80076 | <1% | 371 | $3K | |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 112 | $3K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 2,469 | $3K |
| 99153 | Mod sedat endo service >5yrs | <1% | 306 | $3K |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 242 | $3K |
| Q0138 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | <1% | 19 | $3K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 70 | $3K |
| 86200 | <1% | 223 | $3K | |
| 83655 | <1% | 204 | $3K | |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 563 | $3K |
| 93225 | <1% | 51 | $3K | |
| 36000 | <1% | 99 | $3K | |
| 83013 | <1% | 41 | $3K | |
| 82746 | <1% | 276 | $3K | |
| G0008 | Administration of influenza virus vaccine | <1% | 122 | $3K |
| 90686 | <1% | 114 | $3K | |
| 84270 | <1% | 125 | $3K | |
| 77338 | <1% | 14 | $3K | |
| 88141 | <1% | 454 | $3K | |
| 82977 | <1% | 171 | $2K | |
| 86304 | <1% | 149 | $2K | |
| 93246 | <1% | 51 | $2K | |
| 12002 | <1% | 27 | $2K | |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | <1% | 397 | $2K |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 893 | $2K |
| 95912 | <1% | 27 | $2K | |
| 84146 | <1% | 124 | $2K | |
| 81015 | <1% | 708 | $2K | |
| 29581 | <1% | 51 | $2K | |
| 87420 | <1% | 132 | $2K | |
| 86696 | <1% | 67 | $2K | |
| 86038 | <1% | 138 | $2K | |
| 86800 | <1% | 96 | $2K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 2,946 | $2K |
| 82950 | <1% | 265 | $2K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 27 | $2K |
| 87075 | <1% | 120 | $2K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,132 | $2K |
| 82805 | <1% | 47 | $2K | |
| 86812 | <1% | 56 | $2K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 344 | $2K |
| 51798 | <1% | 68 | $2K | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 186 | $2K |
| 64491 | <1% | 17 | $2K | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 107 | $1K |
| 86695 | <1% | 67 | $1K | |
| 87073 | <1% | 101 | $1K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 36 | $1K |
| 93970 | <1% | 13 | $1K | |
| 36592 | <1% | 49 | $1K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 3,293 | $1K |
| 86706 | <1% | 113 | $1K | |
| 87046 | <1% | 120 | $1K | |
| 76820 | <1% | 15 | $1K | |
| 86300 | <1% | 55 | $1K | |
| 87045 | <1% | 102 | $1K | |
| 93270 | <1% | 43 | $1K | |
| 86256 | <1% | 78 | $1K | |
| 80299 | <1% | 26 | $1K | |
| 83002 | <1% | 66 | $1K | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 281 | $1K |
| 87088 | <1% | 155 | $1K | |
| 82951 | <1% | 46 | $1K | |
| 83718 | <1% | 142 | $990.41 | |
| 73552 | <1% | 14 | $966.54 | |
| 83921 | <1% | 46 | $933.72 | |
| 84478 | <1% | 145 | $931.80 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 770 | $914.79 |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | <1% | 12 | $878.63 |
| 88173 | <1% | 15 | $867.94 | |
| 97167 | <1% | 13 | $856.36 | |
| 82150 | <1% | 68 | $844.56 | |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | <1% | 525 | $829.19 |
| 83520 | <1% | 135 | $827.86 | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 14 | $813.43 |
| 76770 | <1% | 12 | $772.79 | |
| 86308 | <1% | 58 | $771.62 | |
| 97032 | <1% | 42 | $744.86 | |
| 89051 | <1% | 93 | $742.03 | |
| J9190 | Injection, fluorouracil, 500 mg | <1% | 208 | $728.60 |
| 87338 | <1% | 54 | $724.86 | |
| 82465 | <1% | 142 | $719.39 | |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 121 | $706.96 |
| 88112 | <1% | 26 | $678.98 | |
| 86225 | <1% | 48 | $631.33 | |
| 86364 | <1% | 57 | $596.99 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 438 | $586.89 |
| 87641 | <1% | 12 | $545.96 | |
| 84436 | <1% | 103 | $533.65 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 407 | $515.76 |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 144 | $504.73 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 370 | $500.60 |
| 82627 | <1% | 26 | $498.90 | |
| 93242 | <1% | 17 | $448.93 | |
| 97803 | <1% | 12 | $431.68 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 2,032 | $424.52 |
| A6258 | Transparent film, sterile, more than 16 sq. in. but less than or equal to 48 sq. in., each dressing | <1% | 163 | $414.16 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 433 | $412.38 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 13 | $407.10 |
| J3490 | Unclassified drugs | <1% | 657 | $394.42 |
| 84165 | <1% | 45 | $376.35 | |
| A4351 | Intermittent urinary catheter; straight tip, with or without coating (teflon, silicone, or silicone elastomer, etc.), each | <1% | 148 | $371.97 |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 250 | $356.93 |
| 97012 | <1% | 23 | $351.31 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 366 | $341.57 |
| 97168 | <1% | 14 | $322.55 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 225 | $274.35 |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | <1% | 17 | $270.29 |
| 84300 | <1% | 68 | $264.80 | |
| 84630 | <1% | 13 | $261.18 | |
| J0136 | Injection, acetaminophen (b braun), not therapeutically equivalent to j0131, 10 mg | <1% | 600 | $246.12 |
| 82565 | <1% | 45 | $233.35 | |
| 84155 | <1% | 61 | $197.57 | |
| 80354 | <1% | 22 | $192.47 | |
| J0640 | Injection, leucovorin calcium, per 50 mg | <1% | 64 | $161.90 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 332 | $160.67 |
| J1010 | Injection, methylprednisolone acetate, 1 mg | <1% | 177 | $156.95 |
| Q9963 | High osmolar contrast material, 350-399 mg/ml iodine concentration, per ml | <1% | 89 | $155.43 |
| A4216 | Sterile water, saline and/or dextrose, diluent/flush, 10 ml | <1% | 216 | $150.80 |
| 80178 | <1% | 19 | $137.68 | |
| G1010 | Clinical decision support mechanism stanson, as defined by the medicare appropriate use criteria program | <1% | 449 | $132.34 |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 215 | $128.37 |
| 97116 | <1% | 15 | $118.59 | |
| A4213 | Syringe, sterile, 20 cc or greater, each | <1% | 12 | $112.24 |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 41 | $90.15 |
| J1626 | Injection, granisetron hydrochloride, 100 mcg | <1% | 25 | $67.29 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 43 | $62.88 |
| 82009 | <1% | 14 | $59.38 | |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 24 | $54.54 |
| J0295 | Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm | <1% | 42 | $46.32 |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 12 | $39.66 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | <1% | 59 | $38.89 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 43 | $24.25 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 47 | $24.16 |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 48 | $18.79 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 93 | $15.47 |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 16 | $15.42 |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 30 | $15.04 |
| J2470 | Injection, pantoprazole sodium, 40 mg | <1% | 69 | $2.53 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 153 | $0.00 |
| 77002 | 0% | 86 | $0.00 | |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 180 | $0.00 |
| JLL00 | 0% | 38 | $0.00 | |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | 0% | 187 | $0.00 |
| G8988 | Self care functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 27 | $0.00 |
| 88341 | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialVALDEZ, JOSEPH (PRESIDENT CEO)
| Provider | Location | Paid |
|---|---|---|
| ST. Vincent Hospital | Santa Fe, NM | $971K |
| ST. Vincent Hospital | Santa Fe, NM | $546K |
| ST. Vincent Hospital | Santa Fe, NM | $495K |
| ST. Vincent Hospital | Santa Fe, NM | $330K |
| LA Jara Pharmaceutical Center, INC. | La Jara, CO | $313K |
| West Bank Cardiology LLC | Plaquemine, LA | $291K |
| ST. Vincent Hospital | Santa Fe, NM | $162K |
| ST. Vincent Hospital | Santa Fe, NM | $14K |
| ST. Vincent Hospital | Santa Fe, NM | $3K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.